iBET - Instituto de Biologia Experimental e Tecnológica
Categoria(s): Instituições de I&D; Organizações de Investigação por Contrato; Organizações Públicas / Sem Fins Lucrativos
Endereço postal: Avenida da República, Quinta do Marquês, EAN, Apartado 12; 2781-901 Oeiras; Portugal
Palavra(s)-chave: Biomedical engineering, Biotecnologia de células estaminais, Investigação & Desenvolvimento, Novas terapias, Produtos farmacêuticos
iBET is a private non-profit research institution with 30 years of experience in developing innovative solutions for the biopharmaceutical industry, SMEs, academic and private institutions. Key areas of expertise encompasses the development of biopharmaceuticals and novel therapies including vaccines and recombinant proteins for gene therapy; in-vitro models and methodologies for pre-clinical research and stem cells for cell therapy; and structural biology for assisted drug design. In the area of Food and Health, iBET focus is by-products and waste valorization technologies, water, environment and energy nexus, and agro-forestry. iBET’s infrastructure comprises 16 laboratories, a GMP certified Analytical Services Unit and a Pilot Plant providing protein and virus production, bioprocess development technologies and production process scale up services. iBET has access to the GMP manufacturer GenIbet which together present solutions for the development of Biopharmaceuticals for Phase I/II clinical trials. iBET is the coordinator of “iNOVA4Health”, a translational programme involving biomedical researchers in biological understanding of disease, lead compounds and biopharmaceuticals pre-discovery; technological scientists in preclinical development; and clinicians in early clinical and "first-in-man" clinical trials. The institute has several established collaborations with companies such as Bayer, Novartis, Merck, Sanofi, Abbvie, AstraZeneca, among others.